Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645664 | 0.82 | MPL (0.40) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL4550818 | 0.80 | MPL (0.45) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL30580173 | 0.80 | MPL (0.45) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL28952591 | 0.79 | MPL (0.41) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| Hydrochloric Acid SCHEMBL2715685 | 0.79 | MPL (0.44) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL29875817 | 0.79 | MPL (0.41) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL2716488 | 0.79 | MPL (0.41) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL2713811 | 0.79 | MPL (0.41) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL17053066 | 0.79 | GABRA1 (0.42) | MPLSLC6A3SLC6A4SLC6A2KDM2B | |
| SCHEMBL22792332 | 0.78 | ALOX5 (0.48) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | MPL 323/4885SLC6A3 3686/4885SLC6A4 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.